Induction of apoptosis and activation of NF-κB by CD95 require different signalling thresholds

被引:77
作者
Legembre, P
Barnhart, BC
Zheng, LX
Vijayan, S
Straus, SE
Puck, J
Dale, JK
Lenardo, M
Peter, ME
机构
[1] Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA
[2] NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA
[3] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA
[4] NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA
关键词
autoimmune lymphoproliferative syndrome; Fas; lpr(cg); MAPK; NF-kappa B;
D O I
10.1038/sj.embor.7400280
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutations in the death domain of the death receptor CD95 (APO-1/Fas) cause lymphoproliferation and autoimmune disease in both lpr(cg) mice and in patients with autoimmune lymphoproliferative syndrome (ALPS) type Ia. By testing lymphocytes from ALPS type Ia patients, comparing heterozygous with homozygous lprcg mice and coexpressing wild-type and mutant CD95 receptors, we demonstrate that induction of apoptosis requires two wild-type alleles of CD95. By contrast, nuclear factor-kappaB (NF-kappaB) can be fully activated in cells expressing both a mutant and a wild-type CD95 allele, suggesting different thresholds to activate the two signalling pathways. This was confirmed by testing lymphocytes from heterozygous lpr mice, which showed reduced sensitivity to CD95-mediated apoptosis but normal activation of NF-kappaB when compared with wild-type mice. Mutations in CD95 may eliminate the tumour-suppressive function of CD95, at the same time allowing induction of survival or proliferative pathways, which could contribute to the increased risk for lymphoma seen in ALPS type Ia patients.
引用
收藏
页码:1084 / 1089
页数:6
相关论文
共 18 条
[1]   CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells [J].
Barnhart, BC ;
Legembre, P ;
Pietras, E ;
Bubici, C ;
Franzoso, G ;
Peter, ME .
EMBO JOURNAL, 2004, 23 (15) :3175-3185
[2]   Fas engagement induces neurite growth through ERK activation and p35 upregulation [J].
Desbarats, J ;
Birge, RB ;
Mimouni-Rongy, M ;
Weinstein, DE ;
Palerme, JS ;
Newell, MK .
NATURE CELL BIOLOGY, 2003, 5 (02) :118-125
[3]   Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity [J].
Drappa, J ;
Vaishnaw, AK ;
Sullivan, KE ;
Chu, JL ;
Elkon, KB .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (22) :1643-1649
[4]   DOMINANT INTERFERING FAS GENE-MUTATIONS IMPAIR APOPTOSIS IN A HUMAN AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME [J].
FISHER, GH ;
ROSENBERG, FJ ;
STRAUS, SE ;
DALE, JK ;
MIDDELTON, LA ;
LIN, AY ;
STROBER, W ;
LENARDO, MJ ;
PUCK, JM .
CELL, 1995, 81 (06) :935-946
[5]   THE CANDIDATE ONCOPROTEIN BCL-3 IS AN ANTAGONIST OF P50/NF-KAPPA-B-MEDIATED INHIBITION [J].
FRANZOSO, G ;
BOURS, V ;
PARK, S ;
TOMITAYAMAGUCHI, M ;
KELLY, K ;
SIEBENLIST, U .
NATURE, 1992, 359 (6393) :339-342
[6]  
Kimura M, 1994, Int Rev Immunol, V11, P193, DOI 10.3109/08830189409061727
[7]   Pathological findings in human autoimmune lymphoproliferative syndrome [J].
Lim, MS ;
Straus, SE ;
Dale, JK ;
Fleisher, TA ;
Stetler-Stevenson, M ;
Strober, W ;
Sneller, MC ;
Puck, JM ;
Lenardo, MJ ;
Elenitoba-Johnson, KSJ ;
Lin, AY ;
Raffeld, M ;
Jaffe, ES .
AMERICAN JOURNAL OF PATHOLOGY, 1998, 153 (05) :1541-1550
[8]   NF-κB in cancer:: a marked target [J].
Lin, A ;
Karin, M .
SEMINARS IN CANCER BIOLOGY, 2003, 13 (02) :107-114
[9]   Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia [J].
Martin, DA ;
Zheng, LX ;
Siegel, RM ;
Huang, BH ;
Fisher, GH ;
Wang, J ;
Jackson, CE ;
Puck, JM ;
Dale, J ;
Straus, SE ;
Peter, ME ;
Krammer, PH ;
Fesik, S ;
Lenardo, MJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4552-4557
[10]   The CD95(APO-1/Fas) DISC and beyond [J].
Peter, ME ;
Krammer, PH .
CELL DEATH AND DIFFERENTIATION, 2003, 10 (01) :26-35